Pliant Therapeutics (PLRX) Cash from Operations (2019 - 2026)
Pliant Therapeutics (PLRX) posted quarterly Cash from Operations of 19229000.0 for Q1 2026, up 60.65% year-over-year from 11969653.83 in Q1 2025, and down 8.1% quarter-over-quarter from 17788000.0 in Q4 2025.
Pliant Therapeutics (PLRX) Cash from Operations (2019 - 2026) Analysis & Trends
Pliant Therapeutics (PLRX) has reported Cash from Operations for 8 consecutive years, with 19229000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations rose 60.65% year-over-year to 19229000.0; the TTM figure through Mar 2026 stood at 98701000.0 (up 43.31% YoY), while the FY2025 annual figure was 128336000.0, up 17.47% from the prior year.
- Cash from Operations declined to 19229000.0 in Q1 2026 per PLRX's latest filing, from 17788000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 17788000.0 in Q4 2025 and bottomed at 48864000.0 in Q1 2025.
- Historically, Cash from Operations has averaged 30238823.53 across 5 years, with a median of 30271000.0 in 2024.
- Annual changes were most pronounced in 2023 — Cash from Operations slumped 95.83% — and 2025, when it soared 62.68%.
- Pliant Therapeutics' Cash from Operations stood at 31239000.0 in 2022, then increased by 19.65% to 25102000.0 in 2023, then sank by 89.87% to 47662000.0 in 2024, then jumped by 62.68% to 17788000.0 in 2025, then declined by 8.1% to 19229000.0 in 2026.
- Business Quant data shows PLRX's Cash from Operations at 19229000.0 in Q1 2026, 17788000.0 in Q4 2025, and 21081000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.03 Bn | 131.18 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.64 Bn | 77.64 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.93 Bn | 59.75 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.93 Bn | 52.80 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.95 Bn | 36.86 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.51 Bn | 28.20 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.00 Bn | 9.60 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - | 728.46 Mn |
| 10 | Pliant Therapeutics | 71.52 Mn | 71.52 Mn | - | -12.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -12.80 Mn |
| Jun 30, 2026 | -12.80 Mn |
| Mar 31, 2026 | -19.23 Mn |
| Mar 31, 2026 | -19.23 Mn |
| Dec 31, 2025 | -17.79 Mn |
| Dec 31, 2025 | -17.79 Mn |
| Sep 30, 2025 | -21.08 Mn |
| Sep 30, 2025 | -21.08 Mn |
| Jun 30, 2025 | -40.60 Mn |
| Jun 30, 2025 | -40.60 Mn |
| Mar 31, 2025 | -48.86 Mn |
| Mar 31, 2025 | -48.86 Mn |
| Dec 31, 2024 | -47.66 Mn |
| Dec 31, 2024 | -47.66 Mn |
| Sep 30, 2024 | -32.27 Mn |
| Sep 30, 2024 | -32.27 Mn |
| Jun 30, 2024 | -45.30 Mn |
| Jun 30, 2024 | -45.30 Mn |
| Mar 31, 2024 | -30.27 Mn |
| Mar 31, 2024 | -30.27 Mn |